|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
b9664460 |
003 |
CoU |
005 |
20200703183417.3 |
006 |
m o d |
007 |
cr ||||||||||| |
008 |
110125s2011 nyua ob 001 0 eng |
010 |
|
|
|a 2020676723
|
019 |
|
|
|a 750642412
|a 961565934
|a 962704986
|a 988439621
|a 991999059
|a 1037910058
|a 1038644720
|a 1045511469
|a 1055391978
|a 1058442360
|a 1066441158
|a 1081218550
|a 1114411748
|a 1153506125
|
020 |
|
|
|a 9781621004394
|q ebook
|
020 |
|
|
|a 1621004392
|
020 |
|
|
|z 9781612093949
|q hardcover
|
020 |
|
|
|z 1612093949
|
035 |
|
|
|a (OCoLC)ebqac1155227383
|
035 |
|
|
|a (OCoLC)1155227383
|z (OCoLC)750642412
|z (OCoLC)961565934
|z (OCoLC)962704986
|z (OCoLC)988439621
|z (OCoLC)991999059
|z (OCoLC)1037910058
|z (OCoLC)1038644720
|z (OCoLC)1045511469
|z (OCoLC)1055391978
|z (OCoLC)1058442360
|z (OCoLC)1066441158
|z (OCoLC)1081218550
|z (OCoLC)1114411748
|z (OCoLC)1153506125
|
037 |
|
|
|a ebqac3021409
|
040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d YDX
|d N$T
|d E7B
|d OCLCF
|d YDXCP
|d NLGGC
|d EBLCP
|d AZK
|d MERUC
|d AGLDB
|d MOR
|d PIFAG
|d ZCU
|d U3W
|d STF
|d WRM
|d VTS
|d NRAMU
|d ICG
|d REC
|d VT2
|d AU@
|d WYU
|d DKC
|d UX1
|d UKCRE
|d BOL
|
049 |
|
|
|a GWRE
|
050 |
0 |
0 |
|a RM301.25
|
245 |
0 |
0 |
|a Pharmaceutical industry :
|b innovation and developments /
|c David A. Mancuso and Isobel M. Grenada, editors.
|
264 |
|
1 |
|a Hauppauge, N.Y. :
|b Nova Science,
|c c2011.
|
300 |
|
|
|a 1 online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent.
|
337 |
|
|
|a computer
|b c
|2 rdamedia.
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier.
|
340 |
|
|
|g polychrome.
|2 rdacc.
|
347 |
|
|
|a text file
|2 rdaft.
|
490 |
1 |
|
|a Business issues, competition and entrepreneurship.
|
504 |
|
|
|a Includes bibliographical references index.
|
505 |
0 |
|
|a Authorized generic pharmaceuticals : effects on innovation / John R. Thomas -- Authorized generics : an interim report / FTC -- Remarks of J. Thomas Rosch, Commissioner, Federal Trade Commission, before the World Generic Medicine Congress, hearing on "pay-for-delay settlements, authorized generics, and follow-on biologies : thoughts on the how competition law can best protect consumer welfare in the pharmaceutical context" -- Federal R&D, drug discovery, and pricing : insights from the NIH-university-industry relationship / Wendy H. Schacht -- Pharmaceutical R&D and the evolving market for prescription drugs / CBO -- Federal taxation of the drug industry and its effects on new drug development / Gary Guenther -- Pharmaceutical patent litigation settlements : implications for competition and innovation / John R. Thomas -- FDA's authority to regulate drug compounding : a legal analysis / Jennifer Staman -- Promotional spending for prescription drugs / CBO.
|
588 |
|
|
|a Description based on print version record.
|
650 |
|
0 |
|a Drug development.
|
650 |
|
0 |
|a Pharmaceutical industry.
|
650 |
|
0 |
|a Drugs
|x Law and legislation.
|
650 |
|
7 |
|a Drug development.
|2 fast
|0 (OCoLC)fst00898670.
|
650 |
|
7 |
|a Drugs
|x Law and legislation.
|2 fast
|0 (OCoLC)fst00898830.
|
650 |
|
7 |
|a Pharmaceutical industry.
|2 fast
|0 (OCoLC)fst01060129.
|
700 |
1 |
|
|a Mancuso, David A.
|
700 |
1 |
|
|a Grenada, Isobel M.
|
776 |
0 |
8 |
|i Print version:
|t Pharmaceutical industry
|d Hauppauge, N.Y. : Nova Science, c2011.
|z 9781612093949 (hardcover)
|w (DLC) 2011003550.
|
830 |
|
0 |
|a Business issues, competition and entrepreneurship series.
|
856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/ucb/detail.action?docID=3021409
|z Full Text (via ProQuest)
|
907 |
|
|
|a .b96644606
|b 07-07-20
|c 10-03-17
|
998 |
|
|
|a web
|b - -
|c f
|d b
|e z
|f eng
|g nyu
|h 0
|i 2
|
915 |
|
|
|a -
|
956 |
|
|
|a Ebook Central Academic Complete
|
956 |
|
|
|b Ebook Central Academic Complete
|
999 |
f |
f |
|i f123da02-1ce4-522f-b6bd-b0c69166ba86
|s 3854a664-6b48-5385-99aa-f93e74e808ed
|
952 |
f |
f |
|p Can circulate
|a University of Colorado Boulder
|b Online
|c Online
|d Online
|e RM301.25
|h Library of Congress classification
|i web
|n 1
|